Researchers found that gallium-68 PSMA-11 PET/CT significantly affected the planning of definitive radiotherapy for between 16.5% and 37% of patients with localized prostate cancer. The findings in the Journal of Nuclear Medicine suggest that including PSMA PET/CT in the radiotherapy planning process "might improve the success rate of curative-intent prostate radiotherapy," said researcher Dr. Nicholas Nickols.
PSMA PET/CT may increase detection of prostate cancer sites
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.